Mirae Asset Global Investments Co., Ltd. Cerevel Therapeutics Holdings, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$40.88 - $43.27 $197,736 - $209,296	-4,837 Reduced 13.3%	31,526 $1.33 Million
Q4 2023 Jan 24, 2024	BUY	$20.27 - $42.44 $42,911 - $89,845	2,117 Added 6.18%	36,363 $1.54 Million
Q3 2023 Oct 26, 2023	BUY	$20.26 - $31.91 $7,253 - $11,423	358 Added 1.06%	34,246 $747,000
Q2 2023 Aug 10, 2023	BUY	$23.9 - $35.38 $26,672 - $39,484	1,116 Added 3.41%	33,888 $1.08 Million
Q1 2023 May 04, 2023	BUY	$22.82 - $35.32 $181,715 - $281,253	7,963 Added 32.1%	32,772 $799,000
Q4 2022 Feb 09, 2023	BUY	$25.35 - $31.96 $54,806 - $69,097	2,162 Added 9.55%	24,809 $782,000
Q3 2022 Nov 10, 2022	BUY	$25.5 - $41.42 $177,735 - $288,697	6,970 Added 44.46%	22,647 $640,000
Q2 2022 Jul 26, 2022	BUY	$20.62 - $37.15 $323,259 - $582,400	15,677 New	15,677 $414,000

268

155M

2.19M

3.92M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.